Nasdaq

Reviva Pharmaceuticals Reports Completion of Brilaroxazine Long-Term OLE Trial and Upcoming Phase 3 RECOVER-2 Trial Initiation

Reviva Pharmaceuticals Holdings, Inc. announced that 446 participants have completed their long-term open-label extension (OLE) trial for brilaroxazine, with 156 participants receiving one year of ...
Morningstar

CastleVax Announces Initiation of a Phase 2 Study Evaluating Its Mucosally-delivered, Next Generation, COVID-19 Vaccine Candidate

— This Phase 2 study will evaluate the safety, tolerability and systemic/mucosal immunogenicity of CastleVax’s next generation COVID-19 vaccine compared to an approved mRNA vaccine comparator — ...
Seeking Alpha

Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company ...
Business Wire

Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome

LUND, Sweden & EVRY, France--(BUSINESS WIRE)--Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, ...
Seeking Alpha

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...
manilatimes

Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)

Orion Corporation (Orion Pharma) announces initiation of a Phase 2 trial evaluating ODM-212, a potential best-in-class, oral pan-TEAD inhibitor, as a monotherapy in malignant pleural mesothelioma (MPM ...